TrialsgrambetaRCTs are beautiful

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia

This guideline cites 8 of the 199 landmark trials in our Cardiology register.

The 2026 multisociety guideline retires the 2018 Blood Cholesterol guideline and moves US lipid management closer to — but not onto — the European model. Primary prevention stays risk-based: 10-year risk is now estimated with the PREVENT-ASCVD equations (a 'calculate–personalise–possibly reclassify' pathway in which coronary artery calcium resolves the borderline and intermediate strata), and statin intensity follows the risk category rather than a numeric goal. What is new is the secondary-prevention arm, which for the first time names explicit goals — LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL in very-high-risk atherosclerotic disease — which is where the ESC/EAS 2019 guideline with its 2025 Focused Update has stood for years. Lipoprotein(a) should now be measured at least once in every adult, and apoB is endorsed for residual-risk assessment. The register's statin, non-statin and residual-risk trials are grouped by mechanism below.

Statins: intensity & outcomes2

  • 2008JUPITER⁠Cardiology · Lipids · StatinsIn 17,802 adults with LDL < 130 mg/dL and hsCRP ≥ 2 mg/L, rosuvastatin reduced major vascular events versus placebo.HR 0.56Read →
  • 19944S Core⁠Cardiology · Lipids · StatinsIn 4,444 patients with CAD and total cholesterol 5.5–8.0 mmol/L, simvastatin reduced all-cause mortality compared with placebo.RR 0.7Read →

Non-statin LDL lowering (ezetimibe, PCSK9, bempedoic acid)4

  • 2023CLEAR Outcomes⁠Cardiology · Lipids · Non-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
  • 2018ODYSSEY OUTCOMES⁠Cardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
  • 2017FOURIER⁠Cardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
  • 2015IMPROVE-IT⁠Cardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →

Residual risk: triglycerides & inflammation1

  • 2019REDUCE-IT⁠Cardiology · Lipids · TriglyceridesIn 8,179 statin-treated patients with high triglycerides, icosapent ethyl reduced major adverse cardiovascular events compared with placebo.HR 0.75Read →

Lipids in the cardiometabolic patient1

  • 2023SELECT Core⁠Cardiology · Cardiometabolic · GLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →

Cited landmark trials not yet in the register5

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 1995WOSCOPS

    Pravastatin in primary prevention — the first trial to show statin benefit in men without prior infarction.

  • 2002HPS (Heart Protection Study)

    Simvastatin cut vascular events across a broad high-risk population regardless of baseline LDL-C.

  • 2010CTT meta-analyses

    The Cholesterol Treatment Trialists' patient-level meta-analyses — the quantitative basis of the 'lower is better' dose-response.

  • 2020ORION-10/-11

    Inclisiran (siRNA) for sustained LDL-cholesterol lowering with twice-yearly dosing.

  • 2022PROMINENT

    Pemafibrate lowered triglycerides but did not reduce cardiovascular events — the reason fibrates are not recommended for risk reduction.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.